For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

After adjustment for confounding variables, researchers found no increased suicide risk for GLP-1 receptor agonists versus DPP-4 inhibitors or SGLT-2 inhibitors.

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative ...

Image credit: James Manning – PA Images/Getty Images. Glucagon-like peptide-1 receptor agonists (GLP-1) drugs are a class of medications used to manage type 2 diabetes and treat obesity.

A large population-based cohort study reports that using GLP-1 RAs significantly reduces the risk for cardiovascular events ...

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast 2023-2033 Research and Markets Wed, Feb 19, 2025, 10:09 AM 3 min read ...

A Central Illinois cardiologist breaks down the potential benefits of GLP-1 medications on heart health. It was one of the ...

Back to Healio Sodium-glucose cotransporter 2, or SGLT2, inhibitors may be more cardioprotective for older adults, whereas glucagon-like peptide-1 receptor agonists may confer greater HbA1c ...